Pharmaceutical marketing has reached a critical inflection point. What began as a pandemic-driven digital surge has evolved into something far more nuanced: a sophisticated hybrid model where traditional and digital channels coexist strategically, each playing distinct roles in the marketing mix.
The post-COVID "new normal" isn't a return to pre-pandemic strategies, nor is it an unchecked leap into digital-only marketing. Instead, it represents a fundamental restructuring of how pharmaceutical brands engage with healthcare professionals and patients, one where the field force remains the largest investment area, digital channels have plateaued at maturity, and broadcast advertising is experiencing a strategic resurgence through Connected TV.
This transformation raises critical questions:
- Where should pharma invest its marketing dollars in 2026 and beyond?
- Which channels deliver the highest ROI?
- How is Marketing Mix Modeling itself evolving to meet the demands of omnichannel strategies and AI-powered optimization?
Over the past six years, Axtria has conducted 170+ Marketing Mix (MMx) studies across 80+ pharmaceutical brands spanning 19 therapy areas. Unlike survey-based reports, this analysis is built on actual performance data: real spending patterns, measured ROI, and proven channel effectiveness from January 2019 through December 2024. The insights cover products at all lifecycle stages: launch (12%), growth (41%), and mature (47%).
This comprehensive benchmarking reveals where the industry has been, where it stands today, and where it's heading.
This report will show you:
- The true state of the hybrid model: Discover why digital spending has stabilized, where television is making a strategic comeback, and which channel combinations are delivering the highest effectiveness in the post-COVID landscape.
- Channel ROI patterns you need to know: Understand which digital sub-channels consistently outperform and where Connected TV is transforming the effectiveness equation.
- The future of marketing mix: Learn why annual analysis is obsolete, how AI-powered always-on optimization is reshaping measurement, and what cross-channel attribution reveals about true marketing impact.
- Strategic imperatives for competitive advantage: Identify the six specific actions that leading organizations are taking in 2026, and access implementation roadmaps that maximize ROI at every product lifecycle stage.
Why this report matters now
The competitive gap is widening. Organizations leading this transformation are running always-on MMx. They are leveraging AI optimization and measuring omnichannel synergy. And they are dynamically allocating budgets based on real-time performance. Those relying on annual analysis and manual processes are falling behind measurably.
The data speaks for itself. With 170+ studies backing every insight, this is evidence of what's actually working across the industry. Whether you're optimizing a mature brand's efficiency, scaling a growth brand's impact, or planning a launch strategy, these benchmarks provide the competitive intelligence you need.
Marketing Mix Modeling is transforming. The evolution from retrospective measurement to proactive optimization represents a fundamental shift in how marketing performance drives strategic decisions. Organizations that adapt their MMx capabilities will gain sustainable, competitive advantages across ROI and positioning.
What you’ll walk away with:
- Precise benchmarks for spend allocation across Field Force, Digital, TV, and Conferences by brand lifecycle stage
- Detailed ROI trends for each channel and digital sub-channel from 2019-2024
- Clear understanding of when to use each channel for maximum impact
- Practical frameworks for implementing omnichannel strategies that amplify effectiveness
- Implementation roadmap for AI-powered, always-on MMx capabilities
- Competitive intelligence showing where industry leaders are investing, and winning
This report is built for:
- Chief Marketing Officers seeking data-driven investment strategies
- Brand Leaders optimizing channel mix and budget allocation
- Commercial Analytics Teams building advanced MMx capabilities
- Marketing Operations Leaders implementing omnichannel measurement
- Strategic Planners benchmarking against industry performance
Stay ahead of the transformation reshaping pharmaceutical marketing. Understand where the industry is investing, what's delivering results, and how MMx itself is evolving to meet tomorrow's challenges. For a detailed conversation around how these insights apply to your specific brands, therapy areas, and marketing challenges, request a customized readout with Axtria's industry-leading MMx experts.
Read Also: Unlocking Promotional Success: Insights from 140+ Marketing Mix Studies (2024) — an earlier Axtria report that provides foundational benchmarks on promotional ROI and channel prioritization across pharma brands.
Recommended insights
Reports
Reports
White Paper